GO
Loading...

Enter multiple symbols separated by commas

Eli Lilly and Co

More

  • LONDON, July 2- Alarmed by rising resistance to antibiotics, the main line of defence against bacterial infections, scientists and governments are taking a fresh look at bacteria-chomping viruses first isolated a century ago from the stools of patients recovering from dysentery. So-called bacteriophages, which attack bacteria but leave human cells...

  • Eli Lilly and Cree are big market movers Thursday, 25 Jun 2015 | 4:46 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Eli Lilly and Co., up $2.54 to $84.80. Lindsay Corp., up $7.08 to $89.70.

  • US STOCKS-Wall St little changed; health stocks rally Thursday, 25 Jun 2015 | 1:38 PM ET

    *UnitedHealth biggest boost to the Dow; Eli Lilly to S&P. UnitedHealth Group jumped as much as 2.5 percent to $122.13 and was the biggest boost to the Dow. Among hospital operators, shares of Community Health Systems were up 12.6 percent at $62.28 after touching a record high of $63.36, while shares of HCA Holdings rose 8.6 percent to $90.55 and Tenet Healthcare...

  • INDIANAPOLIS— Eli Lilly received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug. Shares of the Indianapolis drugmaker climbing in premarket trading. Alimta brought in $2.79 billion in sales globally last year as...

  • June 12- The Alzheimer's Association may not offer an early look at highly sought clinical trial data on an experimental drug from Eli Lilly and Co after news of the impending release led to a jump in the company's shares. A spokesman for the Alzheimer's Association told Reuters on Thursday that the abstracts, summaries of clinical trial data to be presented at...

  • June 12- The Alzheimer's Association may not offer an early look at highly sought clinical trial data on an experimental drug from Eli Lilly and Co after news of the impending release led to a jump in the company's shares. A spokesman for the Alzheimer's Association told Reuters on Thursday that the abstracts, summaries of clinical trial data to be presented at...

  • Top 5 stocks of the week and how to trade them Friday, 12 Jun 2015 | 10:15 AM ET
    Bottles of Eli Lilly's Cymbalta on a pharmacy shelf in Princeton, Illinois.

    CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.

  • Early movers: TWTR, BOJA, URBN, WSM, GOOG & more Friday, 12 Jun 2015 | 7:47 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Lilly shares sizzle as investors await Alzheimer's data Thursday, 11 Jun 2015 | 9:18 PM ET

    June 11- Shares of Eli Lilly and Co have jumped 10 percent this week, confounding many industry experts, amid speculation investors were placing bets ahead of expected long-term data on an Alzheimer's disease treatment once considered a dud. Limited data from an abstract of the trial, called Expedition Ext, are expected to be released by the Alzheimer's...

  • *IMF says major differences remain with Greece. *Citrix jumps after investor sends letter to board. Shares of Eli Lilly rose 4.3 percent to $86.77, a day after it said one of its drugs met main goals in two pivotal Phase III studies.

  • Which stocks seduce women vs. men Wednesday, 10 Jun 2015 | 10:03 AM ET
    Traders work on the floor of the New York Stock Exchange.

    You can see the demographic changes of stocks, as some are becoming more masculine, while others more feminine, according to data from SigFig.

  • Your first trade for Wednesday Tuesday, 9 Jun 2015 | 6:24 PM ET
    Fast Money Final Trade:  COST, NXPI, RNF & SAVE

    The "Fast Money" traders give their final trades of the day.

  • The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...

  • Where the profits are: 10 picks Monday, 8 Jun 2015 | 8:00 AM ET

    As most U.S. companies struggle to grow profits this year, some S&P 500 firms could be poised to buck the trend, a new report shows.

  • June 6- A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. More patients in the studies who received Lilly's basal insulin peglispro also got their blood sugar down to the...

  • FDA panel to discuss Lilly's lung cancer drug approval Tuesday, 2 Jun 2015 | 11:10 AM ET

    June 2- The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly& Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly's experimental drug, necitumumab, and chemotherapy...

  • Trading pharma: 5 plays on Bristol's rough day Friday, 29 May 2015 | 6:47 PM ET
    Bristol-Myers Squibb R&D headquarters.

    Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...